|
1
|
Saeed W, Shahbaz E, Maqsood Q, Ali SW and
Mahnoor M: Cutaneous oncology: Strategies for melanoma prevention,
diagnosis, and therapy. Cancer Control. 31:107327482412749782024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Domingues B, Lopes JM, Soares P and Pópulo
P: Melanoma treatment in review. Immunotargets Ther. 7:35–49. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sullivan RJ and Flaherty KT: Major
therapeutic developments and current challenges in advanced
melanoma. Br J Dermatol. 170:36–44. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kruczała M, Ziobro M, Grela-Wojewoda A and
Cedrych I: Advanced skin melanoma-systemic treatment. OncoReview.
5:133–138. 2015. View Article : Google Scholar
|
|
5
|
Stockwell BR: Ferroptosis turns 10:
Emerging mechanisms, physiological functions, and therapeutic
applications. Cell. 185:2401–2421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang C, Liu X, Jin S, Chen Y and Guo R:
Ferroptosis in cancer therapy: A novel approach to reversing drug
resistance. Mol Cancer. 21:472022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan H, Pratte J and Giardina C:
Ferroptosis and its potential as a therapeutic target. Biochem
Pharmacol. 186:1144862021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao L, Zhou X, Xie F and Zhang L, Yan H,
Huang J, Zhang C, Zhou F, Chen J and Zhang L: Ferroptosis in cancer
and cancer immunotherapy. Cancer Commun (Lond). 42:88–116. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bholah TC, Neergheen-Bhujun VS, Hodges NJ,
Dyall SD and Bahorun T: Cytoglobin as a biomarker in cancer:
Potential perspective for diagnosis and management. Biomed Res Int.
2015:8245142015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chakraborty S, John R and Nag A:
Cytoglobin in tumor hypoxia: Novel insights into cancer
suppression. Tumour Biol. 35:6207–6219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoang DV, Thuy LTT, Hai H, Hieu VN, Kimura
K, Oikawa D, Ikura Y, Dat NQ, Hoang TH, Sato-Matsubara M, et al:
Cytoglobin attenuates pancreatic cancer growth via scavenging
reactive oxygen species. Oncogenesis. 11:232022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shivapurkar N, Stastny V, Okumura N,
Girard L, Xie Y, Prinsen C, Thunnissen FB, Wistuba II, Czerniak B,
Frenkel E, et al: Cytoglobin, the newest member of the globin
family, functions as a tumor suppressor gene. Cancer Res.
68:7448–7456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oleksiewicz U, Liloglou T, Field JK and
Xinarianos G: Cytoglobin: Biochemical, functional and clinical
perspective of the newest member of the globin family. Cell Mol
Life Sci. 68:3869–3883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujita Y, Koinuma S, De Velasco MA, Bolz
J, Togashi Y, Terashima M, Hayashi H, Matsuo T and Nishio K:
Melanoma transition is frequently accompanied by a loss of
cytoglobin expression in melanocytes: A novel expression site of
cytoglobin. PLoS One. 9:e947722014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye S, Xu M, Zhu T, Chen J, Shi S, Jiang H,
Zheng Q, Liao Q, Ding X and Xi Y: Cytoglobin promotes sensitivity
to ferroptosis by regulating p53-YAP1 axis in colon cancer cells. J
Cell Mol Med. 25:3300–3311. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
De Backer J, Maric D, Zuhra K, Bogaerts A,
Szabo C, Vanden Berghe W and Hoogewijs D: Cytoglobin silencing
promotes melanoma malignancy but sensitizes for ferroptosis and
pyroptosis therapy response. Antioxidants (Basel). 11:15482022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Demartino AW, Amdahl MB, Bocian K, Rose
JJ, Tejero J and Gladwin MT: Redox sensor properties of human
cytoglobin allosterically regulate heme pocket reactivity. Free
Radical Biol Med. 162:423–434. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oleksiewicz U, Liloglou T, Tasopoulou KM,
Daskoulidou N, Bryan J, Gosney JR, Field JK and Xinarianos G:
Cytoglobin has bimodal: Tumour suppressor and oncogene functions in
lung cancer cell lines. Hum Mol Genet. 22:3207–3217. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu J, Minikes AM, Gao M, Bian H, Li Y,
Stockwell BR, Chen ZN and Jiang X: Intercellular interaction
dictates cancer cell ferroptosis via NF2-YAP signalling. Nature.
572:402–406. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han X, Duan X, Liu Z, Long Y, Liu C, Zhou
J, Li N, Qin J and Wang Y: ZEB1 directly inhibits GPX4
transcription contributing to ROS accumulation in breast cancer
cells. Breast Cancer Res Treat. 188:329–342. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kelderman S, Schumacher TNM and Haanen J:
Acquired and intrinsic resistance in cancer immunotherapy. Mol
Oncol. 8:1132–1139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang D, Chen X, Kang R and Kroemer G:
Ferroptosis: Molecular mechanisms and health implications. Cell
Res. 37:107–125. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lei G, Mao C, Yan Y, Zhuang L and Gan B:
Ferroptosis, radiotherapy, and combination therapeutic strategies.
Protein Cell. 12:836–857. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lei G, Zhuang L and Gan B: Targeting
ferroptosis as a vulnerability in cancer. Nat Rev Cancer.
22:381–396. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Talty R and Bosenberg M: The role of
ferroptosis in melanoma. Pigment Cell Melanoma Res. 35:18–25. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elgendy SM, Alyammahi SK, Alhamad DW,
Abdin SM and Omar HA: Ferroptosis: An emerging approach for
targeting cancer stem cells and drug resistance. Crit Rev Oncol
Hemat. 155:1030952020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu B, Chen XB, Ying MD, He QJ, Cao J and
Yang B: The role of ferroptosis in cancer development and treatment
response. Front Pharmacol. 8:9922017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valashedi MR, Bamshad C, Najafi-Ghalehlou
N, Nikoo A, Tomita K, Kuwahara Y, Sato T, Roushandeh AM and
Roudkenar MH: Non-coding RNAs in ferroptotic cancer cell death
pathway: Meet the new masters. Hum Cell. 35:972–994. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang K, Wu L, Zhang P, Luo M, Du J, Gao
T, O'Connell D, Wang G, Wang H and Yang Y: miR-9 regulates
ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in
melanoma. Mol Carcinog. 57:1566–1576. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Masaldan S, Bush AI, Devos D, Rolland AS
and Moreau C: Striking while the iron is hot: Iron metabolism and
ferroptosis in neurodegeneration. Free Radic Biol Med. 133:221–233.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown CW, Amante JJ, Chhoy P, Elaimy AL,
Liu H, Zhu LJ, Baer CE, Dixon SJ and Mercurio AM: Prominin2 drives
ferroptosis resistance by stimulating iron export. Dev Cell.
51:575–586. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gorr TA, Wichmann D, Pilarsky C,
Theurillat JP, Fabrizius A, Laufs T, Bauer T, Koslowski M, Horn S,
Burmester T, et al: Old proteins-new locations: Myoglobin,
haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer
cells. Acta Physiol (Oxf). 202:563–581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Demirci S, Doğan A, Apdik H, Tuysuz EC,
Gulluoglu S, Bayrak OF and Sahin F: Cytoglobin inhibits migration
through PI3K/AKT/mTOR pathway in fibroblast cells. Mol Cell
Biochem. 437:133–142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Backer JD, Razzokov J, Hammerschmid D,
Mensch C, Hafideddine Z, Kumar N, van Raemdonck G, Yusupov M, Van
Doorslaer S, Johannessen C, et al: The effect of reactive oxygen
and nitrogen species on the structure of cytoglobin: A potential
tumor suppressor. Redox Biol. 19:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee J, You JH, Kim MS and Roh JL:
Epigenetic reprogramming of epithelial-mesenchymal transition
promotes ferroptosis of head and neck cancer. Redox Biol.
37:1016972020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen X, Kang R, Kroemer G and Tang D:
Broadening horizons: The role of ferroptosis in cancer. Nat Rev
Clin Oncol. 18:280–296. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oliveira T, Hermann E, Lin D, Chowanadisai
W, Hull E and Montgomery M: HDAC inhibition induces EMT and
alterations in cellular iron homeostasis to augment ferroptosis
sensitivity in SW13 cells. Redox Biol. 47:1021492021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hangauer MJ, Viswanathan VS, Ryan MJ, Bole
D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL,
et al: Drug-tolerant persister cancer cells are vulnerable to GPX4
inhibition. Nature. 551:247–250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chiang SK, Chen SE and Chang LC: The role
of HO-1 and its crosstalk with oxidative stress in cancer cell
survival. Cells. 10:24012021. View Article : Google Scholar : PubMed/NCBI
|
